Adeno-associated virus 2-mediated antiangiogenic cancer gene therapy: long-term efficacy of a vector encoding angiostatin and endostatin over vectors encoding a single factor.

Academic Article

Abstract

  • Angiogenesis is characteristic of solid tumor growth and a surrogate marker for metastasis in many human cancers. Inhibition of tumor angiogenesis using antiangiogenic drugs and gene transfer approaches has suggested the potential of this form of therapy in controlling tumor growth. However, for long-term tumor-free survival by antiangiogenic therapy, the factors controlling tumor neovasculature need to be systemically maintained at stable therapeutic levels. Here we show sustained expression of the antiangiogenic factors angiostatin and endostatin as secretory proteins by recombinant adeno-associated virus 2 (rAAV)-mediated gene transfer. Both vectors provided significant protective efficacy in a mouse tumor xenograft model. Stable transgene persistence and systemic levels of both angiostatin and endostatin were confirmed by in situ hybridization of the vector-injected tissues and by serum ELISA measurements, respectively. Whereas treatment with rAAV containing either endostatin or angiostatin alone resulted in moderate to significant protection, the combination of endostatin and angiostatin gene transfer from a single vector resulted in a complete protection. These data suggest that AAV-mediated long-term expression of both endostatin and angiostatin may have clinical utility against recurrence of cancers after primary therapies and may represent rational adjuvant therapies in combination with radiation or chemotherapy.
  • Published In

  • Cancer Research  Journal
  • Keywords

  • Angiogenesis Inhibitors, Angiostatins, Animals, Cell Line, Dependovirus, Endostatins, Enzyme-Linked Immunosorbent Assay, Female, Genetic Therapy, Genetic Vectors, Humans, Mice, Mice, Nude, Neoplasm Transplantation, Neoplasms, Transplantation, Heterologous
  • Author List

  • Ponnazhagan S; Mahendra G; Kumar S; Shaw DR; Stockard CR; Grizzle WE; Meleth S
  • Start Page

  • 1781
  • End Page

  • 1787
  • Volume

  • 64
  • Issue

  • 5